Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) CFO Kevin F. Mclaughlin unloaded 10,000 shares of Acceleron Pharma stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $29.78, for a total transaction of $297,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Acceleron Pharma (NASDAQ:XLRN) traded down 0.50% on Friday, hitting $29.81. 140,234 shares of the company’s stock traded hands. Acceleron Pharma has a 52 week low of $16.78 and a 52 week high of $57.89. The stock’s 50-day moving average is $29.63 and its 200-day moving average is $35.97. The company’s market cap is $947.9 million.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings data on Tuesday, August 12th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.01. Analysts expect that Acceleron Pharma will post $-1.44 EPS for the current fiscal year.

A number of research firms have recently commented on XLRN. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday. They set an “outperform” rating and a $47.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $51.00.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.